The Brazilian Health Surveillance Agency (Anvisa) grants the endorsement for the commercialization of four (4) generic medicines unpublished in Brazil. One of them is Entricitabine combined with Tenofovir Fumarate Desoproxil, a product that will be part of the therapeutic arsenal used to treat people living with HIV. The reference product is Truvada, which includes pre-exposure prophylaxis (PReP) used to reduce the risk of sexually acquired infection in high-risk adults. In Brazil, the holder of the registration is Blanver Farmoquímica e Farmacêutica S / A.

Another new generic product with registration approved by Anvisa is Perindopril Erbumine combined with Indapamide, indicated for the treatment of arterial hypertension, also known as high blood pressure. According to the Brazilian Society of Hypertension (SBH), this disease is very common, affecting one in four adults. In this case, the company holding the registration in the country is EMS S / A.

Among the products approved by Anvisa is also the unprecedented generic Bilastine, indicated for the symptomatic treatment of allergic rhinoconjunctivitis (intermittent or persistent) and urticaria. The company that holds the registration is EMS S / A.

Completing the list of the four unpublished generic drugs approved by Anvisa is Testosterone Undecilate. This product will be used in sex hormone replacement therapies in men with primary and secondary hypogonadism. The holder of the registration of this medicine in Brazil is Eurofarma Laboratório S / A.

(…)

For more information go to http://portal.anvisa.gov.br/rss/-/asset_publisher/Zk4q6UQCj9Pn/content/id/4337807